#Tessera technologies inc. prices pro

Tessera expects the combined company to generate pro forma revenues of around $450 million in 2016, half of which will come from product licensing. Get all financial information for Tessera Technologies Inc. Xperi Inc Profile, Financial Information, Stock Quotes Charts.

The acquisition will make Tessera one of the leading product and technology licensing companies globally. Buy 20 packs of select Rotary/Reciprocating files, get 20 off your Endo purchase. The Company plans to introduce a new corporate name, stock ticker, brand and logo during the first quarter of 2017.

#Tessera technologies inc. prices free

The combined company will try to maintain an optimum level of free cash flow available for funding quarterly dividends, pay debts, make investments and finance future acquisitions.Įmergence of a Stronger Entity Following the Merger ('Tessera') and DTS are now combined under Tessera Holding Corporation and the shares of the combined company will continue to trade on the NASDAQ under Tessera's ticker symbol TSRA. Tessera Therapeutics scores 230M to ramp up gene writing tech. Revenue synergies are expected to be achieved once the combined company reaches an optimum level of customer channel and technology utilization, and penetrates its addressable markets. Von Maltzahn also hinted that the companys technology could have value in the liver. It is also expected that the combined entity will realize $15 million in annualized cost synergies within 12 to 18 months of the close of transaction. Tessera expects the deal to be immediately accretive to its earnings per share and free cash flow.